ストックスクリーナーアプリを入手
0.9637
7.34%
-0.0763
アフターアワーズ：
.96
-0.0037
-0.38%
前日終値:
$1.04
開ける：
$1.03
24時間の取引高:
11.52M
Relative Volume:
1.32
時価総額：
$289.20M
収益：
$188.87M
当期純損益:
$-400.38M
株価収益率:
-0.6425
EPS:
-1.5
ネットキャッシュフロー:
$-260.90M
1週間 パフォーマンス:
+4.55%
1か月 パフォーマンス:
-13.18%
6か月 パフォーマンス:
-49.54%
1年 パフォーマンス:
-50.32%
1日の値動き範囲:
$0.96
$1.04
1週間の範囲:
$0.8511
$1.15
52週間の値動き範囲:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
PACB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
0.9637 | 276.62M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-11 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-04-18 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-17 | アップグレード | UBS | Neutral → Buy |
| 2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-06-30 | 開始されました | Goldman | Buy |
| 2023-05-10 | 開始されました | Barclays | Equal Weight |
| 2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Neutral |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-09-27 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 開始されました | Cowen | Outperform |
| 2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | ダウングレード | CL King | Buy → Neutral |
| 2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2016-06-27 | 開始されました | CL King | Buy |
| 2016-04-15 | 開始されました | First Analysis Sec | Overweight |
| 2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-02-04 | 繰り返されました | Maxim Group | Buy |
| 2013-09-26 | 繰り返されました | Maxim Group | Buy |
| 2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
Media resourceS - PacBio
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy - sharewise
PureTarget repeat expansion and carrier panels enable high-throughput clinical research solutions - PacBio
PacBio to Present at Upcoming Investor Conferences - Yahoo Finance
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2025 Earnings Call Transcript - MSN
PacBio Stock Slips Despite New China Distribution Deal With Haorui - Nasdaq
PACB stock touches 52-week low at $0.94 amid market challenges - Investing.com Australia
PacBio (PACB) Expands Presence in China with New Distribution De - GuruFocus
PacBio (PACB) Expands Presence in China with New Distribution Deal | PACB Stock News - GuruFocus
PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene - Yahoo Finance
HiFi sequencing uncovers the secret to aging gracefully in Earth’s oldest living organisms - PacBio
Pacific Biosciences: A Mountain Of Red Flags (NASDAQ:PACB) - Seeking Alpha
Potential Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Not Without Risk - simplywall.st
PACB: Piper Sandler Adjusts Price Target for Pacific Biosciences - GuruFocus
PACB: Piper Sandler Adjusts Price Target for Pacific Biosciences | PACB Stock News - GuruFocus
PACB: Stephens & Co. Reiterates Overweight Rating | PACB Stock N - GuruFocus
Where Pacific Biosciences Stands With Analysts - Benzinga
PACB: Stephens & Co. Reiterates Overweight Rating | PACB Stock News - GuruFocus
PACB Price Target Reduced by Piper Sandler Following Quarterly R - GuruFocus
PACB Price Target Reduced by Piper Sandler Following Quarterly Results | PACB Stock News - GuruFocus
PacBio clears allegations after special investigation By Investing.com - Investing.com Nigeria
Metagenomics Market Size, Share, Forecast & Trends Analysis Report 2025: Market to Soar to $6.71 Billion by 2031, Driven by Agri Genomics and Genome Mapping - GlobeNewswire Inc.
PACB Stock May Rise Following the Deal With Chulalongkorn University - Nasdaq
PacBio (PACB) Completes Probe into Employment Practices and Cybe - GuruFocus
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated - Yahoo Finance
Pacbio adjusts 2025 revenue guidance to $150M-$170M amid macroeconomic challenges - MSN
Pacific Biosciences of California First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
PacBio (PACB) Sees Increased Options Activity Ahead of Earnings - GuruFocus
PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates - Yahoo Finance
Pacific Biosciences of California Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pacific Biosciences (PACB) Beats Revenue Expectations Amid ChallengesNews and Statistics - IndexBox
Pacific Biosciences of California Q1 2025 Earnings Call Transcript - MarketBeat
Pacific Biosciences: Q1 Earnings Snapshot - Norwalk Hour
PacBio Announces First Quarter 2025 Financial Results - GlobeNewswire
Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Pacific Biosciences (PACB) Reports Q1 2025 Financials Amid Macroeconomic Challenges - GuruFocus
PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1 - Yahoo Finance
Earnings call transcript: Pacific Biosciences beats EPS forecast, stock dips By Investing.com - Investing.com India
PacBio Q1 2025 slides: Consumable growth offsets instrument revenue decline - Investing.com Canada
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
PacBio Reports Q1 2025 Financial Results, Announces Restructuring and Strategic Focus Shift - Nasdaq
PacBio (PACB) Sees Increased Options Activity Ahead of Earnings | PACB Stock News - GuruFocus
Pacific Biosciences (PACB) Prepares for Q1 Earnings Announcement - GuruFocus
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
1.38%
大文字化:
|
ボリューム (24 時間):